Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis

T Chiba, H Ohtani, T Mizoi, Y Naito, E Sato, H Nagura, A Ohuchi, K Ohuchi, K Shiiba, Y Kurokawa, S Satomi, T Chiba, H Ohtani, T Mizoi, Y Naito, E Sato, H Nagura, A Ohuchi, K Ohuchi, K Shiiba, Y Kurokawa, S Satomi

Abstract

T-cell infiltration into human cancer tissues can be a manifestation of host immune responses to cancer cells. The present study was undertaken to explore the clinicopathological significance of intraepithelial CD8(+) T cells using 371 consecutively sampled human colorectal carcinomas. By univariate analysis, we noted that the survival curves by intraepithelial CD8(+) T cells became separated only after 1 to 2 years postoperation. Multivariate analyses revealed that the beneficial effect of this factor becomes significant only after a longer (more than 2 year), but not after a shorter (less than 2 year) follow-up period. Furthermore, the number of intraepithelial CD8(+) T cells was significantly higher in patients alive for more than 5 years than in patients who either died of cancer after a curative operation or patients who underwent a noncurative operation. Patients' cancer-specific death long after a curative operation is thought to be caused by the growth of micrometastases in other organs or near the primary sites. The effects of intraepithelial CD8(+) T cells, therefore, may be mediated by suppression of micrometastasis, rather than suppression of growth in the primary tumour. In conclusion, our data support a hypothesis on the presence of systemic immunosurveillance against micrometastasis of cancer cells.

Figures

Figure 1
Figure 1
Immunohistochemical results. Cases with median (A) and highly abundant (B) intraepithelial CD8+ T cells in colorectal carcinoma. Scale bar, 50 μm.
Figure 2
Figure 2
Distribution histogram of the number of intraepithelial CD8+ T cells in colorectal carcinoma (A), showing a distinct asymmetric pattern. Cancer-specific survival curves by intraepithelial CD8+ T cells in all patients (divided into two at the median) (B). The longitudinal axis, cancer-specific cumulative survival rate. The horizontal axis, years after operation. Note an inverse correlation between the number of intraepithelial CD8+ T cells and the stages (C), depicted by Box–Whisker plot showing 25 percentile, median, and 75 percentile.
Figure 3
Figure 3
Morphometric results of the number of intraepithelial CD8+ T cells among different groups. The longitudinal axis, the number of intraepithelial CD8+ T cells. A, Patients alive for more than 5 years (stage I excluded). B, Patients who died of the primary disease after curative operation (stages II and III). C, patients who received noncurative operation (stage IV+stage III with unresectable lymph node metastasis). We excluded cases positive for cancer cells at the resection margins. Overall differences, P<0.0005 (Kruskal–Wallis).
Figure 4
Figure 4
Double staining for CD8 (red) and Ki-67 (brown) (A). Green arrows indicate double positive cells (nucleus labelled in brown, cell surface in red). Red arrows indicate CD8+ T cells without labelling for Ki67. Arrowheads indicate single positivity for Ki-67 in cancer cells. Scale bar, 20 μm. Comparison of the labelling index of Ki-67 between intraepithelial and peritumoral CD8+ T cells (B).

References

    1. Albert ML, Darnell RB (2004) Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer 4: 36–44
    1. Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, Vecchiato N, Macri E, Fornasarig M, Boiocchi M (1999) High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 154: 1805–1813
    1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991–998
    1. Fukuzawa K, Takahashi K, Furuta K, Tagaya T, Ishikawa T, Wada K, Omoto Y, Koji T, Kakumu S (2001) Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). J Gastroenterol 36: 681–688
    1. Hamilton SR, Aaltonen LA (eds) (2000) WHO classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC press
    1. Henderson RA, Finn OJ (1996) Human tumor antigens are ready to fly. Adv Immunol 62: 217–256
    1. Ishikawa T, Fujita T, Suzuki Y, Okabe S, Yuasa Y, Iwai T, Kawakami Y (2003) Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res 63: 5564–5572
    1. Jass J, Cottier DS, Jeevaratnam P, Pokos V, Holdaway KM, Bowden ML, Van de Water NS, Browett P (1995) Diagnostic use of microsatellite instability in hereditary non-polyposis colorectal cancer. Lancet 346: 1200–1201
    1. Jass JR, Love SB, Northover JM (1987) A new prognostic classification of rectal cancer. Lancet 1(8545): 1303–1306
    1. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of ‘tumor escape’ phenotype. Nat Immunol 3: 999–1005
    1. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R (2000) Strategies for immunotherapy of cancer. Adv Immunol 75: 235–282
    1. Menon AG, van Rhijn CMJ, Morreau H, Putter H, Tollenaar RAEM, van de Velde CJH, Fleuren GJ, Kuppen PJK (2004) Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 84: 493–501
    1. Michael-Robinson JM, Biemer-Huttmann A, Purdie DM, Walsh MD, Simms LA, Biden KG, Young JP, Leggett BA, Jass JR, Radford-Smith GL (2001) Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 48: 360–366
    1. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58: 3491–3494
    1. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H (2001) Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61: 5132–5136
    1. Ohtani H, Naito Y, Saito K, Nagura H (1997) Expression of costimulatory molecules B7-1 and B7-2 by macrophages along invasive margin of colon cancer: a possible anti-tumor immunity? Lab Invest 77: 231–241
    1. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411: 380–384
    1. Saiki Y, Ohtani H, Naito Y, Miyazawa M, Nagura H (1996) Immunophenotypical characterization of Epstein–Barr virus-associated gastric carcinoma: massive infiltration by proliferating CD8+ T lymphocytes. Lab Invest 75: 67–76
    1. Saito K, Takeha S, Shiiba K, Matsuno S, Sorsa T, Nagura H, Ohtani H (2000) Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis. Int J Cancer 86: 24–29
    1. Schumacher K, Haensch W, Roefzaad C, Schlag PM (2001) Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 61: 3932–3936
    1. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2: 293–299
    1. Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumours 6th edn. New York: Wiley-Liss
    1. Weninger W, Crowley MA, Manjunath N, von Andrian UH (2001) Migratory properties of naive, effector, and memory CD8T cells. J Exp Med 194: 953–966
    1. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survivalin epithelial ovarian cancer. N Eng J Med 348: 203–213

Source: PubMed

3
Abonnere